Northport

Researchers are comparing the effectiveness of two treatments for participants with stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC) who have PD-L1 expression of 1% or higher. This phase 3, randomized, open-label study focuses on first-line treatment options and aims to evaluate overall survival over up to five years for participants with PD-L1 levels between 1% and 49%. The trial involves participants with measurable disease and good performance status who have not received prior systemic therapy for advanced disease. The study compares a combination of Nivolumab and Relatlimab plus chemotherapy against Pembrolizumab plus chemotherapy. Chemotherapy drugs include Carboplatin, Pemetrexed, and Cisplatin, administered at specified doses on scheduled days. Participants are randomly assigned to receive either the Nivolumab and Relatlimab combination with chemotherapy or Pembrolizumab with chemotherapy as their initial treatment. Treatment schedules and doses are defined but not detailed here. Participants will be closely monitored throughout the study, which may last up to five years. Researchers will assess overall survival as the primary outcome, along with regular imaging tests like CT or MRI to measure disease status. Eligibility screening includes assessing PD-L1 levels, performance status, and other health factors. Safety monitoring and follow-up will continue to evaluate treatment effects and participant well-being during and after treatment.

Researchers are evaluating the effectiveness of Exposure and Response Prevention (ERP) therapy compared to a stress management training control in Veterans with Obsessive Compulsive Disorder (OCD), including those with both OCD and post-traumatic stress disorder (PTSD). This 4-year randomized clinical trial focuses on whether ERP can improve functioning, quality of life, and OCD symptoms among Veterans receiving care at various VA medical centers and telehealth hubs. Participants are randomly assigned to one of two groups: the ERP group receives 16 weekly therapy sessions delivered via video telehealth (VTH), emphasizing exposure to feared situations and prevention of compulsive rituals. The control group receives 16 weekly sessions of stress management training, which includes psychoeducation and skills such as deep breathing, relaxation, positive imagery, assertiveness, and problem solving. Both treatments include homework practice and symptom monitoring. Throughout the study, participants complete assessments at the end of treatment and six months later to measure changes in work and social functioning using the Work and Social Adjustment Scale (WSAS). Those in the ERP group also provide feedback on treatment satisfaction and participate in qualitative interviews about how the therapy affected their functioning and PTSD symptoms. Providers and VA administrators will also be interviewed to evaluate how ERP could be implemented in VA mental health care settings.

Researchers are investigating whether olomorasib combined with pembrolizumab is more effective than pembrolizumab plus placebo for participants with resected KRAS G12C-mutant non-small cell lung cancer (NSCLC) in part A. In part B, they are assessing if olomorasib combined with durvalumab is more effective than durvalumab plus placebo for participants with unresectable KRAS G12C-mutant NSCLC. This Phase 3 study may last up to 3 years for each participant.